United States - English - NLM (National Library of Medicine)

teva parenteral medicines, inc. - daunorubicin hydrochloride (unii: ud984i04lz) (daunorubicin - unii:zs7284e0zp) - daunorubicin 5 mg in 1 ml - daunorubicin hydrochloride injection in combination with other approved anticancer drugs is indicated for remission induction in acute nonlymphocytic leukemia (myelogenous, monocytic, erythroid) of adults and for remission induction in acute lymphocytic leukemia of children and adults. daunorubicin hydrochloride is contraindicated in patients who have shown a hypersensitivity to it.

United States - English - NLM (National Library of Medicine)

hikma pharmaceuticals usa inc. - daunorubicin hydrochloride (unii: ud984i04lz) (daunorubicin - unii:zs7284e0zp) - daunorubicin hydrochloride in combination with other approved anticancer drugs is indicated for remission induction in acute nonlymphocytic leukemia (myelogenous, monocytic, erythroid) of adults and for remission induction in acute lymphocytic leukemia of children and adults. daunorubicin hydrochloride is contraindicated in patients who have shown a hypersensitivity to it.

United States - English - NLM (National Library of Medicine)

hisun pharmaceuticals usa, inc. - daunorubicin hydrochloride (unii: ud984i04lz) (daunorubicin - unii:zs7284e0zp) - daunorubicin hydrochloride injection in combination with other approved anticancer drugs is indicated for remission induction in acute nonlymphocytic leukemia (myelogenous, monocytic, erythroid) of adults and for remission induction in acute lymphocytic leukemia of children and adults. daunorubicin hydrochloride injection is contraindicated in patients who have shown a hypersensitivity to it.

United States - English - NLM (National Library of Medicine)

hisun pharmaceuticals usa, inc. - daunorubicin hydrochloride (unii: ud984i04lz) (daunorubicin - unii:zs7284e0zp) - daunorubicin hydrochloride injection in combination with other approved anticancer drugs is indicated for remission induction in acute nonlymphocytic leukemia (myelogenous, monocytic, erythroid) of adults and for remission induction in acute lymphocytic leukemia of children and adults. daunorubicin hydrochloride injection is contraindicated in patients who have shown a hypersensitivity to it.

United States - English - NLM (National Library of Medicine)

hisun pharmaceuticals usa, inc. - daunorubicin hydrochloride (unii: ud984i04lz) (daunorubicin - unii:zs7284e0zp) - daunorubicin hydrochloride injection in combination with other approved anticancer drugs is indicated for remission induction in acute nonlymphocytic leukemia (myelogenous, monocytic, erythroid) of adults and for remission induction in acute lymphocytic leukemia of children and adults. daunorubicin hydrochloride injection is contraindicated in patients who have shown a hypersensitivity to it.

New Zealand - English - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - daunorubicin hydrochloride 2.14 mg/ml equivalent to daunorubicin 2 mg/ml - solution for injection - 2 mg/ml - active: daunorubicin hydrochloride 2.14 mg/ml equivalent to daunorubicin 2 mg/ml excipient: sodium chloride water for injection - daunorubicin injection is indicated for the treatment of the following: · acute lymphocytic (lymphoblastic) leukaemia: daunorubicin is usually reserved for use in cases shown to be resistant to other drugs. however, combined treatment with daunorubicin, vincristine and a steroid has been used in the early stages of this disease.

United States - English - NLM (National Library of Medicine)

halison pharmaceuiticals usa, inc - daunorubicin hydrochloride (unii: ud984i04lz) (daunorubicin - unii:zs7284e0zp) - daunorubicin 20 mg in 4 ml

United States - English - NLM (National Library of Medicine)

jazz pharmaceuticals, inc. - cytarabine (unii: 04079a1rdz) (cytarabine - unii:04079a1rdz), daunorubicin (unii: zs7284e0zp) (daunorubicin - unii:zs7284e0zp) - cytarabine 100 mg in 20 ml - vyxeos is indicated for the treatment of newly-diagnosed therapy-related acute myeloid leukemia (t-aml) or aml with myelodysplasia-related changes (aml-mrc) in adults and pediatric patients 1 year and older. the use of vyxeos is contraindicated in patients with the following: risk summary based on anecdotal data of cytarabine in pregnant women and results of studies of daunorubicin and cytarabine in animals, vyxeos can cause embryo-fetal harm when administered to a pregnant woman. there are no adequate and well-controlled studies of vyxeos, daunorubicin, or cytarabine in pregnant women. daunorubicin and cytarabine are reproductive and developmental toxicants in multiple species (mice, rats, and/or dogs), starting at a dose that was approximately 0.02 times the exposure in patients at the recommended human dose on a mg/m2 basis [see animal data] . patients should be advised to avoid becoming pregnant while taking vyxeos. if this drug is used during pregnancy, or if the patient becomes pregnant while taking th

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer (perth) pty ltd - daunorubicin hydrochloride, quantity: 2.14 mg/ml - injection, solution - excipient ingredients: sodium chloride; hydrochloric acid; sodium hydroxide; water for injections - - acute lymphocytic (lymphoblastic) leukaemia. daunorubicin is usually reserved for use in cases shown to be resistant to other drugs. however, combined treatment with daunorubicin, vincristine and a steroid has been used in the early stages of the disease. - acute myeloblastic leukaemia. daunorubicin has been used in all stages, alone or in combination with other cytotoxic agents e.g., cytarabine. - disseminated solid tumours. daunorubicin has been investigated for use in these tumours and found to be effective in some cases of disseminated neuroblastoma and rhabdomyosarcoma.

European Union - English - EMA (European Medicines Agency)

jazz pharmaceuticals ireland limited - daunorubicin hydrochloride, cytarabine - leukemia, myeloid, acute - antineoplastic agents - vyxeos liposomal is indicated for the treatment of adults with newly diagnosed, therapy-related acute myeloid leukaemia (t-aml) or aml with myelodysplasia-related changes (aml-mrc).